World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
52897
World Ranking
8432
National Ranking
4359

Overview

Kathy S. Albain is affiliated with Loyola University Chicago in the United States. Their research focuses primarily on fields within medicine, specifically oncology and cancer research. Subfields of particular interest include pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, as well as genetics.

Their scholarly work spans several critical topics related to cancer and breast cancer treatment, including:

  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Immunotherapy and Biomarkers

Kathy S. Albain has published extensively in several journals with high output particularly in:

  • Cancer Research
  • Journal of Clinical Oncology
  • UNC Libraries
  • JAMA Oncology
  • npj Breast Cancer

Notable recent papers include:

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer, 2020, JAMA Oncology
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial, 2021, Cancer Cell
  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer, 2020, JAMA Oncology
  • Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival, 2020, JNCI Journal of the National Cancer Institute

The research collaborations of Kathy S. Albain include frequent co-authorship with several scholars such as:

  • Lajos Pusztai
  • Hope S. Rugo
  • Claudine Isaacs
  • Rita Nanda
  • Laura J. Esserman

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

    Laura F. Hutchins;Joseph M. Unger;John J. Crowley;Charles A. Coltman

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

    Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

    Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow

  • Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

    Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice

  • Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

    Kathy S. Albain;John J. Crowley;Michael LeBlanc;Robert B. Livingston

  • Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.

    M M Le Beau;K S Albain;R A Larson;J W Vardiman

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study

    Antoinette J. Wozniak;John J. Crowley;Stanley P. Balcerzak;Geoffrey R. Weiss

  • Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

    Karen Kelly;Kari Chansky;Laurie E. Gaspar;Kathy S. Albain

  • The Global Breast Cancer Burden: Variations in Epidemiology and Survival

    Gabriel N. Hortobagyi;Jaime de la Garza Salazar;Kathleen Pritchard;Dino Amadori

  • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

    Halle C F Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle

  • Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

    Nicholas Robert;Brian Leyland-Jones;Lina Asmar;Robert Belt

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

    Rita Nanda;Minetta C Liu;Christina Yau;Rebecca Shatsky

  • Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Hope S. Rugo;Olufunmilayo I. Olopade;Angela DeMichele;Christina Yau

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
Claudine Isaacs
Claudine Isaacs Georgetown University
David R. Gandara
David R. Gandara University of California, Davis
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
William E. Barlow
William E. Barlow Fred Hutchinson Cancer Research Center
Robert B. Livingston
Robert B. Livingston University of Arizona
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Dawn L. Hershman
Dawn L. Hershman Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

There are numerous online degrees in healthcare that can complement or provide alternative pathways to traditional medical studies in the USA. For those aiming for healthcare leadership roles rather than becoming a physician, online mha programs cahme accredited offer flexible, respected routes into hospital administration and health services management.

Registered nurses looking to advance their education might consider rn to bsn programs without clinicals. These programs are ideal for working nurses seeking career growth without the need for additional clinical hours, making them both efficient and accessible.

For nurses aspiring to reach the highest level of practice, options like the fastest dnp program can dramatically shorten the time required for a Doctor of Nursing Practice degree. Some may also prefer dnp programs without dissertation which eliminate the need for lengthy research projects, allowing students to focus on clinical leadership and patient care.

Exploring these alternative online healthcare degrees opens doors to a diverse range of career opportunities within the medical field, providing flexibility and targeted professional growth for both aspiring and current healthcare professionals.

Best Scientists Citing Kathy S. Albain

Trending Scientists

Recently Published Articles